anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Ixekizumab administered by two 80 milligram (mg) subcutaneous (SC) injections at Week 0, then one 80 mg SC injection every 2 weeks (Q2W) at week 2, 4, 6, 8 and 10. Starting from Week 12, 80 mg Ixekizumab Prefilled Syringe was administered by one 80 mg SC injection every 4 weeks (Q4W).
Solid oral dosage formulations, such as tablet, mini-tab, multiparticulates or osmotic delivery systems, are coated with a mucoadhesive polymeric coating or formed of a mucoadhesive polymer to increase oral bioavailability of Biopharmaceutical Classification System (BCS) Class I drugs. Representative BCS I drugs include valacyclovir, gabapentin, furosemide, levodopa, metformin, and ranitidine HCl. The inclusion of mucoadhesives in the solid oral dosage form brings the dosage form into close proximity with the target epithelium and facilitates diffusion of drug into intestinal tissue. The mucoadhesive polymer may be either dispersed in the matrix of the tablet or applied as a direct compressed coating to the solid oral dosage form. Preferred mucoadhesive polymers include poly(adipic)anhydride “P(AA)” and poly(fumaric-co-sebacic)anhydride “P(FA:SA)”. Other preferred mucoadhesive polymers include non-erodable polymers such as DOPA-maleic anhydride co polymer; isopthalic anhydride polymer; DOPA-methacrylate polymers; and DOPA-cellulosic based polymers.
The participants in the intervention group will receive the routine care plus the ICory-Solution which is the surgical pathway currently practiced in the study hospital. The ICory-Solution has two components: (1) the Buddy Healthcare mobile app (BuddyCare) that provides a comprehensive day-by-day perioperative guide for parents regarding their child's surgery with an interface for health care professionals to monitor parents' and their children's needs as well as communicate with them. (2) The Triumf Health mobile game app that provides emotional support and distraction to children.
PURPOSE: An H3N8 equine influenza virus is provided to manufacture a naturally attenuated H3N8 equine influenza virus vaccine. CONSTITUTION: An H3N8 equine influenza virus (accession number KCTC 12158BP) is isolated from a horse. The virus has 351th-373th sites of a nonstructural protein (NS) gene, which are deleted. The NS gene has a base sequence of sequence number 5. A vaccine composition contains the virus. A kit for diagnosing the virus contains the virus or an antigen thereof.
NEW MATERIAL:A compound shown by the formula I [X is H, or Z (Z is group shown by the formula II, formula III, etc.); Y is Z when X is H, and Y is CH3 when X is Z]. EXAMPLE:1-(3,3-Dimethylcyclohexan-1-yl)3-buten-1-ol. USE:An imparter or an enhancer for durable fragrance and flavor, and an intermediate for other organic syntheses. Having improved fragrance and flavor of citrus, fruity woody, tobacco-like, or camphor-like flower fragrant tone, useful for food and drink perfume, healthy and hygienic articles and drugs, etc. PREPARATION:A compound shown by the formula IV is reacted in dimethylformamide in the presence of POCl3 to give a compound shown by the formula V, which is catalytically reduced with hydrogen in the presence of both triethylamine and Lindlar catalyst, to give a compound shown by the formula VI. This compound is brought into contact with a compound shown by the formula VII (X is halogen), to give a compound shown by the formula I where X is H and Y is group shown by the formula II.
A method of inhibiting coronavirus infection comprising administering interferon to at least a portion of the upper respiratory tract of a person at risk of being exposed to a coronavirus is provided. The interferon may be selected from the group consisting of a Type I interferon, a Type II interferon, a Type III interferon, or combination thereof. The Type I interferon may be interferon-alpha (IFN-α) or interferon-beta (IFN-β). The Type II interferon may be interferon-gamma (IFN-γ). The Type III interferon may be interferon-lambda (IFN-λ). The interferon may be dosed through inhalation of an aerosol, spray, mist, or powder comprising the interferon. The interferon may be administered by means of an aerosol nebuliser. The coronavirus may be SAR-CoV-2 (COVID-19). The method may involve administration of between 1 and 1000 micrograms of interferon.
FIELD: pharmacy, biochemistry. SUBSTANCE: invention describes four variants of pharmaceutical compositions. Composition comprises pyranone compound as pharmaceutically active agent, basic amine taken in the amount from about 0.1% to about 10% of total weigh of composition, one or some pharmaceutically acceptable solvents and one or some pharmaceutically acceptable non-ionogenic surface-active substances. Pyranone compound is inhibitor of retrovirus protease. Composition can comprise additionally one or some pharmaceutically acceptable oils. Composition is in the form of self-emulsifying composition and provides high concentration and high oral availability of lipophilic compounds of pyranone. EFFECT: improved properties of composition. 31 cl, 1 tbl, 11 ex
BACKGROUND: Obesity is a widely recognized global public health issue, and bariatric surgery has emerged as an effective intervention for alleviating obesity associated health complications. However, the impact of bariatric surgery on male reproductive function remains inconclusive in the literature. The current understanding of the impact of laparoscopic sleeve gastrectomy (LSG) on male reproductive function remains ambiguous, despite its status as the most commonly performed bariatric surgery. This prospective cohort study aimed to investigate the impact of LSG on erectile function and semen quality.
PATIENTS AND METHODS: A total of 34 obese patients were enrolled in this study and underwent LSG. Prior to the operation and at 3, 6, and 12 months postoperation, all participants were required to complete the International Index of Erectile Function-5 (IIEF-5) questionnaire and undergo a nocturnal erectile function test and semen quality analysis.
RESULTS: Within 12 months postoperation, BMI, blood lipids, and insulin resistance showed significant improvement. The IIEF-5 score increased significantly (18.88±5.97 vs. 23.78±3.19, P <0.05), and the frequency and duration of erections significantly improved compared to baseline. Sperm concentration, total motility, survival rate, and sperm morphology parameters exhibited a significant decline at 3 months but demonstrated a significant improvement at 6 and 12 months postoperation. At 12 months, sperm concentration was shown to be correlated with changes in zinc (r=0.25, P =0.033) as well as changes in testosterone (r=0.43, P =0.013).
CONCLUSIONS: LSG has beneficial effects on erectile function, despite a transient decline in semen quality at 3 months postoperatively, followed by a significant improvement at 12 months.
Patients receive phenelzine sulfate PO QD on days -7 to -4, and then BID on days -3 to 21. Patients receive docetaxel IV over 60 minutes on day 1. Treatment repeats every 21 days for at least 12 weeks in the absence of disease progression or unacceptable toxicity.
Participants in the dual-task training group will receive exercises involving both motor and cognitive functions.Dual-task training sessions will begin with 10 minutes of stretching and proceed with 20 minutes of motor-cognitive dual-task exercises (counting backwards from 30 on double stance, naming the months and singing when standing on soft surfaces, finding words that starts with a given letter etc.) and sessions will end with 10 minutes of cooling.Exercises will be applied for 8 weeks 2 days a week each session will last for 30 minutes.
AIM: The aim of this study is to explore the key mechanisms of perioperative neurocognitive dysfunction (PND) after anesthesia/surgery (A/S) by screening hub genes.
METHODS: Transcriptome sequencing was conducted on hippocampal samples obtained from 18-month-old C57BL/6 mice assigned to control (Ctrl) and A/S groups. The functionality of differentially expressed genes (DEGs) was investigated using Metascape. Hub genes associated with changes between the two groups were screened by combining weighted gene coexpression network analysis within CytoHubba. Reverse transcription PCR and western blotting were used to validate changes in mRNA and protein expression, respectively. NLRP3 inflammasome activation was detected by western blotting and ELISA. Tauroursodeoxycholic acid (TUDCA), an inhibitor of endoplasmic reticulum (ER) stress, was administrated preoperatively to explore its effects on the occurrence of PND. Immunofluorescence analysis was performed to evaluate the activation of astrocytes and microglia in the hippocampus, and hippocampus-dependent learning and memory were assessed using behavioral experiments.
RESULTS: In total, 521 DEGs were detected between the control and A/S groups. These DEGs were significantly enriched in biological processes related to metabolic processes and their regulation. Four hub genes (Hspa5, Igf1r, Sfpq, and Xbp1) were identified. Animal experiments have shown that mice in the A/S group exhibited cognitive impairments accompanied by increased Hspa5 and Xbp1 expression, ER stress, and activation of NLRP3 inflammasome.
CONCLUSIONS: Inhibiting ER stress alleviated cognitive impairment in A/S mice; particularly, ER stress induced by A/S results in NLRP3 inflammasome activation and neuroinflammation. Moreover, the preoperative administration of TUDCA inhibited ER stress, NLRP3 inflammasome activation, and neuroinflammation.
PROBLEM TO BE SOLVED: To obtain a support bindable to a somatostatin receptor, to be used for preparing detectable element-bearing medicinal agents, by binding a chelate group to a somatostatin peptide. SOLUTION: This derivative, a somatostantin derivative, is obtained by chemically binding a chelate group to the terminal amino group of a somatostatin peptide. This derivative is to be used as a support for detectable elements. The support is bindable to a somatostaitn receptor; therefore, after supporting a radioactive element thereon, can be used as e.g. a medicine for treating somatostaitn receptor-positive tumor, or as an imaging reagent for in vivo diagnoses. The somatostatin analog mentioned above is e.g. a derivative of the formula (A is a 7-10C phenylakyl, etc.; A' is H, an alkyl, etc.; Y1 and Y2 are each a direct bond, H, etc.; B is Phe or Tyr; C is a (substituted)(L)-Trp, etc.; D is Lys, etc.; E is Thr, Ser, etc.; G is COOR7 , etc.; R7 is H, etc.).
Clinical studies of Oxacillin for Injection did not include sufficient number of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. 

This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. 

Oxacillin for Injection contains 63.77 mg (2.77 mEq) of sodium per gram oxacillin. At the usual recommended doses, patients would receive between 63.77 and 382.62 mg/day (2.77 and 16.62 mEq) of sodium. The geriatric population may respond with a blunted natriuresis to salt loading. This may be clinically important with regard to such diseases as congestive heart failure.
Myopathy, defined as muscle aching or muscle weakness in conjunction with increases in creatine phosphokinase (CPK) values to greater than 10 times the upper limit of normal (ULN), has been reported with the use of daptomycin. Rhabdomyolysis, with or without acute renal failure, has been reported [see Adverse Reactions ( 6.2)] . 

Patients receiving daptomycin for injection should be monitored for the development of muscle pain or weakness, particularly of the distal extremities. In patients who receive daptomycin for injection, CPK levels should be monitored weekly, and more frequently in patients who received recent prior or concomitant therapy with an HMG-CoA reductase inhibitor or in whom elevations in CPK occur during treatment with daptomycin for injection.

In adult patients with renal impairment, both renal function and CPK should be monitored more frequently than once weekly [see Use in Specific Populations ( 8.6) and Clinical Pharmacology ( 12.3)] . 

In Phase 1 studies and Phase 2 clinical trials in adults, CPK elevations appeared to be more frequent when daptomycin was dosed more than once daily. Therefore, daptomycin should not be dosed more frequently than once a day.

Daptomycin should be discontinued in patients with unexplained signs and symptoms of myopathy in conjunction with CPK elevations to levels >1,000 U/L (~5× ULN), and in patients without reported symptoms who have marked elevations in CPK, with levels >2,000 U/L (≥10× ULN). In addition, consideration should be given to suspending agents associated with rhabdomyolysis, such as HMG-CoA reductase inhibitors, temporarily in patients receiving daptomycin [see Drug Interactions ( 7.1)] .
The invention discloses a medicament for treating chronic respiratory disease of chicken and a preparation method thereof. The medicament is prepared from the following Chinese herbal medicinal raw materials in parts by mass: 45 to 50 parts of sea-ear shell, 40 to 50 parts of cassia occidentalis, 45 to 50 parts of Chinese atractylode rhizome, 45 to 50 parts of platycodon grandiflorum, 30 to 40 parts of Chinese rhubarb, 30 to 40 parts of baical skullcap root, 30 to 40 parts of dried tangerine peel, 30 to 40 parts of lightyellow sophora root, 30 to 40 parts of liquorice, 30 to 40 parts of cape jasmine, 30 to 40 parts of turmeric root-tuber, 90 to 100 parts of houttuynia cordata, and 50 to 65 parts of perilla leaf. The preparation method comprises the following steps: weighing a certain amount of the Chinese medicinal raw materials in mass parts; and crushing, screening and mixing to prepare the medicinal powder. The medicament for treating chronic respiratory disease of chicken is suitable for lung heat cough, mouth breathing, respiratory rale, anepithymia and other symptoms. Large scale application proves that the medicament has quick response and good curative effect. The medicament is a pure Chinese medicinal preparation, has no residue, toxic or side effect compared with the western medicaments.
Approximately 20 participants whose most recent anti-cancer therapy consisted of single-agent PD-1/PD-L1 blockade and achieved unconfirmed partial response or stable disease will receive GDC-0919, at the MTD or MAD determined during the dose-escalation stage, in combination with atezolizumab. Treatment may continue until unacceptable toxicity or disease progression with an unfavorable risk-benefit ratio.
BACKGROUND: Coronary artery calcium (CAC) is heterogeneous in older age and is incompletely explained by traditional atherosclerotic cardiovascular disease risk factors. The extremes of subclinical atherosclerosis burden are strongly associated with either a low or high 10-year risk of incident atherosclerotic cardiovascular disease, respectively. However, the genetic underpinnings of differences in arterial aging remain unclear. We sought to determine the independent association of 2 polygenic scores for coronary heart disease (CHD) with CAC in adults ≥75 years of age.
METHODS: There were 1865 ARIC (Atherosclerosis Risk in Communities) participants who underwent genetic testing at visit 1 (1987-1989) and CAC scans at visit 7 (2018-2019). In the primary analysis, an externally derived multi-ancestry polygenic CHD risk score was calculated for both White and Black participants. Results were confirmed using a separate ARIC-derived polygenic CHD risk score, including ≥6 million variants computed for White participants. We used multivariable logistic regression models to assess the association of polygenic CHD risk with CAC, after adjusting for baseline, time-averaged lifestyle, traditional risk factors, and local ancestry principal components.
RESULTS: In the primary analysis, the average age was 80.6 years old, 61.6% were women, and the median CAC score was 246 (189 participants with CAC=0, 364 participants with CAC≥1000). Compared with persons below the 20th percentile of polygenic CHD risk, persons with polygenic-CHD risk above the 80th percentile had 82% lower odds of having CAC=0 (odds ratio, 0.18 [95% CI, 0.09-0.37]) and had >4-fold higher odds of CAC≥1000 (odds ratio, 4.77 [95% CI, 2.88-7.88]). On a continuous scale, each SD increment increase in the polygenic risk score was associated with a 78% higher CAC score. Results were nearly identical using a second confirmatory polygenic CHD risk score in White participants.
CONCLUSIONS: Polygenic CHD risk is robustly associated with a lower prevalence of CAC=0 and a higher prevalence of CAC≥1000 in adults ≥75 years of age, beyond lifestyle and traditional risk factors. These results suggest a heritable contribution to distinct healthy and unhealthy arterial aging phenotypes that persist throughout the life course.
The blister has been designed to make oral contraceptive dosing as easy and as convenient as possible. The tablets are arranged in four rows of seven tablets each, with the days of the week appearing on the blister above the first row of tablets.

Note: Each blister has been preprinted with the days of the week, starting with Sunday, to facilitate a Sunday-Start regimen. Six different day label strips have been provided with the Detailed Patient & Brief Summary Patient Package Insert in order to accommodate a Day-1 Start regimen. If the patient is using the Day-1 Start regimen, she should place the self-adhesive day label strip that corresponds to her starting day over the preprinted days.

Important: The patient should be instructed to use an additional method of protection until after the first week of administration in the initial cycle when utilizing the Sunday-Start regimen.

The possibility of ovulation and conception prior to initiation of use should be considered.
An infusion pump is configured to determine a confidence in a patient weight value that is used to determine one or more treatment parameters. The infusion pump includes a display configured to display, a keypad, a processor in communication with the display, and a memory in communication with the processor. The memory stores instructions that when executed by the processor cause the execution of a patient weight check. The patient weight check determines a patient weight value corresponding to a weight of a medical patient to receive an infusion therapy from the infusion pump according to one or more treatment parameters, and a reference weight value corresponding to a weight estimate of the medical patient. The patient weight check determines that a difference between the patient weight value and the reference weight value violates a threshold condition and provides an indication to the user of the violation. The patient weight check receives a confirmation associated with the patient weight value, determines the one or more treatment parameters using the patient weight value, and provides the infusion therapy to the patient according to the one or more treatment parameters.
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive behavioral and cognitive impairments. Despite growing evidence of the neuroprotective action of omega-3 polyunsaturated fatty acids (PUFAs), the effects and mechanism of omega-3 PUFAs on AD control are yet to be clarified. By crossing male heterozygous fat-1 mice with female APP/PS1 mice, we assessed whether elevated tissue omega-3 PUFA levels could alleviate AD progression and their underlying mechanism among the offspring WT, APP/PS1 and APP/PS1 × fat-1 groups at various stages. We found that the fat-1 transgene significantly increased brain omega-3 PUFA and docosahexaenoic acid (DHA) levels, and cognitive deficits together with brain Aβ-40 and Aβ-42 levels in 6-month-old APP/PS1 × fat-1 mice were significantly lower than those in APP/PS1 mice. Subsequently, the tandem mass tag (TMT) method revealed the elevated expression of cortex and hippocampus myelin-associated glycoprotein (MAG) in APP/PS1 × fat-1 mice at 2-6 months. Furthermore, GO and KEGG pathway enrichment analysis suggested that the MAG-related myelin sheath pathway and its interaction with AD were regulated by omega-3 PUFAs. Moreover, subsequent western blot assays showed that both increased endogenous omega-3 levels and in vitro supplemented DHA up-regulated MAG expression, and the AD-protective effects of DHA on LPS-induced BV2 cells were significantly weakened when MAG was inhibited by si-RNA transfection. In summary, our study suggested that omega-3 PUFAs might protect against AD by up-regulating MAG expression.
A handheld medical processing device for providing a physician with medical information and storage for medical information. The medical processing device includes a processor and a memory unit within the device. A touch display screen is provided on a face of the device and connected to the processor. A recording device is provided for recording audio signals and a disk drive stores data input to the device on a recording medium by contacting the touch screen. The processor generates a menu of options for display on the display screen. Options for operation of the device are selectable by contacting the display screen at a display position of the desired menu option. The menu options allow the physician to input data by contacting the display screen, input audio data to be recorded by the recording device and prepare a prescription by contacting the display screen. The application software used by the processor is stored in the memory and data input on the touch screen is selectively saved in one of the memory or the recording medium. The memory also stores a database of medical information and the menu generated by the processor includes an option for accessing the database. An input/output port is also provided for connection of a peripheral device, the peripheral device is able to provide a scanned image to the processor for display, the device being able to increase and decrease the magnitude of the image.
The majority of human cancers inactivate the p53 tumor suppressor network, and consequently, p53 is one of the most studied proteins in cancer biology. Peering into the intricacies of the p53 network should provide insight into the etiology of cancer, which may lead to the identification of molecular targets for therapeutic intervention. p53 carries out its tumor suppressor functions by inducing potent biological outputs, such as programmed cell death, in cells destined for becoming cancerous. p53 is a transcription factor that can regulate expression of numerous genes. The present invention discloses a novel method of rapidly determining the critical p53 target genes that can be utilized for therapeutic intervention. Additionally, this invention discloses suppression of MCAK as a treatment of human cancers and other diseases where p53 levels are elevated.